Recent Updates
Recently added Catalysts
EHTH Positive Sentiment Score: 75/100

Document eHealth, Inc. Announces Second Quarter 2024 Results Strong second quarter results driven by Medicare segment growth YoY Raises 2024 Annual Guidance

Key Takeaway: eHealth, Inc. reported its financial results for the second quarter of 2024, highlighting strong growth in its Medicare segment. The company has raised its annual guidance for 2024, anticipating total revenue between $470 million and $495 million. Although it faced a slight decrease in total revenue and an increase in GAAP net loss, other metrics such as Non-GAAP total revenue and Medicare applications showed positive growth. The firm remains optimistic about its prospects amid upcoming changes in Medicare Advantage plans.

Market Sentiment Analysis

POSITIVE FACTORS

  • Significant growth in Medicare application volume driven by agency and carrier platforms.
  • Improved Non-GAAP total revenue excluding net adjustment revenue by 13% year-over-year.
  • Raised 2024 annual guidance expectations for total revenue and adjusted EBITDA.

CONCERNS & RISKS

  • GAAP net loss increased to $28 million, a 19% rise compared to Q2 2023.
  • Total revenue decreased by 1% year-over-year, showing slight decline on the surface.

Full Press Release Details

eHealth, Inc. Announces Second Quarter 2024 Results
Strong second quarter results driven by Medicare segment growth YoY
Raises 2024 Annual Guidance
AUSTIN, Texas - August 7, 2024 - eHealth, Inc. (Nasdaq EHTH), a leading private online health insurance marketplace, today announced its financial results for the second quarter ended June 30, 2024.
CEO Comments
"eHealth delivered another quarter of strong execution generating significant growth in second quarter Medicare application volume across our agency and carrier-dedicated Amplify platforms. Our existing book of business continued to generate positive net adjustment revenue, driven by favorable retention and cash collection trends. On the expense side, we continued to find savings within our fixed cost base and improved per member acquisition costs in our Medicare agency business, compared to the second quarter of 2023. Our AEP preparations are now in full swing. We expect significant changes in Medicare Advantage plans this year. Combined with a continuing reduction in the industry's broker fulfillment capacity, we believe this creates an opportunity to drive strong consumer demand to our platform during the enrollment season. We are well prepared to take advantage of this opportunity while providing best-in-class service to Medicare beneficiaries." - Fran Soistman, Chief Executive Officer
Q2 2024 total revenue of $65.9 million decreased 1% year-over-year, including $11.5 million in positive net adjustment revenue, as compared to Q2 2023 total revenue of $66.8 million, which includes $18.7 million of positive net adjustment revenue.
Q2 2024 Non-GAAP total revenue excluding net adjustment revenue(1) increased 13% year-over-year.
Q2 2024 Medicare submissions(a) across our core agency and carrier-dedicated Amplify platforms grew 16% compared to Q2 2023.
Q2 2024 Medicare Advantage LTV increased 4% to $927 from $891 in Q2 2023, driven primarily by favorable carrier and contract mix as well as constraint reduction.
Q2 2024 pre-tax impairment and restructuring charges of $3.0 million related to lease exits and other cost-reduction efforts.
Q2 2024 GAAP net loss of $28.0 million increased 19%, compared to Q2 2023 GAAP net loss of $23.5 million
Q2 2024 Non-GAAP net loss(1), which excludes the post-tax impact of positive net adjustment revenue and impairment and restructuring charges, improved 9% year-over-year.
Q2 2024 adjusted EBITDA(1) of $(15.5) million compared to Q2 2023 adjusted EBITDA(1) of $(14.8) million Q2 2024 adjusted EBITDA excluding net adjustment revenue(1) improved $6.5 million year-over-year driven primarily by Medicare Advantage approved member growth and improved LTVs as well as continued fixed cost reduction efforts.
Cash, cash equivalents and marketable securities of $151.1 million as of June 30, 2024.
Commissions receivable balance of $831.9 million as of June 30, 2024.
Note See the tables at the end of this press release for a reconciliation of our GAAP financial measures to our non-GAAP financial measures for the relevant periods and footnote (1) on page 15 at the end of this press release for definitions of our non-GAAP financial measures.
(a) Submissions describe applications that are submitted by individuals online through our eHealth platform or completed with the assistance of our benefit advisors where the individual provides authorization to the benefit advisor to submit the application to the insurance carrier partner. The individual may have additional actions to take before the application will be reviewed by the insurance carrier and not all submissions ultimately become approved members.
Based on information available as of August 7, 2024, we are revising guidance for the full year ending December 31, 2024. These expectations are forward-looking statements and we assume no obligation to update these statements. Actual results may be materially different and are affected by the risk factors and uncertainties identified in this press release and in eHealth's annual and quarterly reports filed with the Securities and Exchange Commission.
The following guidance is for the full year ending December 31, 2024
Total revenue is expected to be in the range of $470.0 million to $495.0 million compared to our prior guidance of $450.0 million to $475.0 million.
GAAP net income (loss) is expected to be in the range of $(36.5) million to $(22.0) million compared to our prior guidance of $(40.0) million to $(20.0) million.
Adjusted EBITDA(1) is expected to be in the range of $7.5 million to $25.0 million compared to our prior guidance of $(5.0) million to $20.0 million.
Operating cash flow is expected to be in the range of $(10.0) million to $0.0 million compared to our prior guidance of $(15.0) million to $(5.0) million.
The above guidance includes the expected impact of positive net adjustment revenue in the range of $14 to $20 million, compared to our prior guidance impact of positive net adjustment revenue in the range of $0 to $15 million. Excluding the impact of positive net adjustment revenue in both years, the mid-point of our 2024 guidance reflects approximately 15% growth in Non-GAAP total revenue excluding net adjustment revenue(1) and a substantial improvement in Non-GAAP net income (loss)(1) and adjusted EBITDA excluding net adjustment revenue(1).
Note See accompanying footnotes on page 15.
Webcast and Conference Call Information
A webcast and conference call will be held today, Wednesday, August 7, 2024 at 8 30 a.m. Eastern Time 7 30 a.m. Central Time. Individuals interested in listening to the conference call may do so by dialing (800) 245-3047. The participant passcode is 1407192. The live and archived webcast of the call will also be available under "News and Events" on the Investor Relations page of our website at https ir.ehealthinsurance.com.
We're Matchmakers. For over 25 years, eHealth has helped millions of Americans find the healthcare coverage that fits their needs at a price they can afford. As a leading independent licensed insurance agency and advisor, eHealth offers access to over 180 health insurers, including national and regional companies.
Forward-Looking Statements
This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding our expectations regarding our business, operations and strategy our estimates regarding total membership, Medicare, individual and family plan, ancillary products and small business memberships our estimates regarding constrained lifetime values of commissions per approved member by product category our estimates regarding costs per approved member our 2024 annual guidance for total revenue, GAAP net income (loss), adjusted EBITDA and operating cash flow the expected impact of positive net adjustment revenue on our 2024 annual guidance and other statements regarding our future operations, financial condition, prospects and business strategies.
These forward-looking statements are inherently subject to various risks and uncertainties that could cause actual results to differ materially from the statements made. In particular, we are required by Accounting Standards Codification 606 - Revenue from Contracts with Customers to make numerous assumptions that are based on historical trends and our management's judgment. These assumptions may change over time and have a material impact on our revenue recognition, guidance, and results of operations. Please review the assumptions stated in this press release carefully.
The risks and uncertainties that could cause our results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to retain existing members and enroll new members during the annual healthcare open enrollment period, the Medicare annual enrollment period, the Medicare Advantage annual open enrollment period and other special enrollment periods changes in laws, regulations and guidelines, including in connection with healthcare reform or with respect to the marketing and sale of Medicare plans such as the Policy and Technical Changes to Medicare Advantage for Contract Year 2025 released by CMS on April 4, 2024 competition, including competition from government-run health insurance exchanges and other sources the seasonality of our business and the fluctuation of our operating results our ability to accurately estimate membership, lifetime value of commissions and commissions receivable changes in product offerings among carriers on our ecommerce platform and changes in our estimated conversion rate of an approved member to a paying member and the resulting impact of each on our commission revenue the concentration of our revenue with a small number of health insurance carriers our ability to execute on our growth strategy and other business initiatives changes in our management and key employees our ability to hire, train, retain and ensure the productivity of licensed insurance agents, or benefit advisors, and other personnel exposure to security risks and our ability to safeguard the security and privacy of confidential data our relationships with health insurance carriers the success of our carrier advertising and sponsorship program our success in marketing and selling health insurance plans and our unit cost of acquisition our ability to effectively manage our operations as our business evolves and execute on our business transformation plan and other strategic initiatives the need for health insurance carrier and regulatory approvals in connection with the marketing of Medicare-related insurance products changes in the market for private health insurance consumer satisfaction of our service and actions we take to improve the quality of enrollments changes in member conversion rates changes in commission rates our ability to sell qualified health insurance plans to subsidy-eligible individuals and to enroll subsidy-eligible individuals through government-run health insurance exchanges our ability to derive desired benefits from investments in our business, including membership growth and retention initiatives our reliance on marketing partners the success and cost of our marketing efforts, including branding, online advertising, direct-to-consumer mail, email, social media, telephone, television, radio and other marketing efforts timing of receipt and accuracy of commission reports payment practices of health insurance carriers dependence on our operations in China the restrictions in our debt obligations the restrictions in our investment agreement with our convertible preferred stock investor our ability to raise additional capital compliance with insurance, privacy, cybersecurity and other laws and regulations the outcome of litigation in which we may from time to time be involved the performance, reliability and availability of our information technology systems, ecommerce platform and underlying network infrastructure, including any new systems we may implement public health crises, pandemics, natural disasters, changing climate conditions and other extreme events general economic conditions, including inflation, recession, financial, banking and credit market disruptions and our ability to effectively administer our self-insurance program. Other factors that could cause operating, financial and other results to differ are described in our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on the Investor Relations page of our website at https ir.ehealthinsurance.com and on the Securities and Exchange Commission's website at www.sec.gov.
All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Relations Contact
Kate Sidorovich, CFA
Senior Vice President, Investor Relations Strategy
investors ehealth.com
https ir.ehealthinsurance.com
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, unaudited)
June 30, 2024 December 31, 2023
Assets
Current assets
Cash and cash equivalents $ 126,344 $ 115,722
Short-term marketable securities 24,721 5,930
Accounts receivable 1,183 3,993
Contract assets - commissions receivable - current 194,306 244,663
Prepaid expenses and other current assets 9,298 12,044
Total current assets 355,852 382,352
Contract assets - commissions receivable - non-current 637,568 673,514
Property and equipment, net 4,355 4,864
Operating lease right-of-use assets 13,435 22,767
Restricted cash 3,090 3,090
Other assets 24,315 26,758
Total assets $ 1,038,615 $ 1,113,345
Liabilities, convertible preferred stock and stockholders' equity
Current liabilities
Accounts payable $ 4,957 $ 7,197
Accrued compensation and benefits 20,012 40,800
Accrued marketing expenses 7,842 20,340
Short term debt 68,662 -
Lease liabilities - current 7,360 7,070
Other current liabilities 7,463 3,131
Total current liabilities 116,296 78,538
Long-term debt - 67,754
Deferred income taxes - non-current 27,057 29,687
Lease liabilities - non-current 24,380 28,333
Other non-current liabilities 4,970 4,949
Total liabilities 172,703 209,261
Convertible preferred stock 317,060 298,053
Stockholders' equity
Common stock 42 41
Additional paid-in capital 808,314 798,786
Treasury stock, at cost (199,998) (199,998)
Retained earnings (accumulated deficit) (59,415) 7,284
Accumulated other comprehensive loss (91) (82)
Total stockholders' equity 548,852 606,031
Total liabilities, convertible preferred stock and stockholders' equity $ 1,038,615 $ 1,113,345
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts, unaudited)
Three Months Ended June 30, % Change Six Months Ended June 30, % Change
2024 2023 2024 2023
Revenue
Commission $ 56,847 $ 60,186 (6) % $ 137,774 $ 128,189 7 %
Other 9,009 6,582 37 % 21,046 12,302 71 %
Total revenue 65,856 66,768 (1) % 158,820 140,491 13 %
Operating costs and expenses (a)
Marketing and advertising (8) 26,783 23,439 14 % 65,520 56,308 16 %
Customer care and enrollment (8) 28,551 29,979 (5) % 61,452 55,050 12 %
Technology and content (8) 13,044 14,453 (10) % 26,349 28,806 (9) %
General and administrative (8) 22,402 25,049 (11) % 42,021 49,373 (15) %
Impairment, restructuring and other charges 3,035 - * 9,348 - *
Total operating costs and expenses 93,815 92,920 1 % 204,690 189,537 8 %
Loss from operations (27,959) (26,152) (7) % (45,870) (49,046) 6 %
Interest expense (2,849) (2,720) (5) % (5,658) (5,300) (7) %
Other income, net 2,335 2,828 (17) % 4,726 4,816 (2) %
Loss before income taxes (28,473) (26,044) (9) % (46,802) (49,530) 6 %
Benefit from income taxes (505) (2,543) (1,850) (6,151)
Net loss (27,968) (23,501) (19) % (44,952) (43,379) (4) %
Preferred stock dividends (5,480) (5,223) (10,960) (10,324)
Change in preferred stock redemption value (5,540) (4,191) (10,787) (7,260)
Net loss attributable to common stockholders $ (38,988) $ (32,915) (18) % $ (66,699) $ (60,963) (9) %
Net loss per share attributable to common stockholders
Basic and diluted $ (1.33) $ (1.18) (13) % $ (2.29) $ (2.20) (4) %
Weighted-average number of shares used in per share
Basic and diluted 29,233 27,822 5 % 29,072 27,735 5 %
_____________________________ (a) Includes stock-based compensation expense as follows
Marketing and advertising $ 711 $ 538 $ 1,355 $ 993
Customer care and enrollment 511 788 1,035 1,393
Technology and content 779 1,173 1,753 2,078
General and administrative 3,105 3,694 6,503 6,723
Total stock-based compensation expense $ 5,106 $ 6,193 (18) % $ 10,646 $ 11,187 (5) %
Non-GAAP Results (1)
Adjusted EBITDA (1) $ (15,540) $ (14,808) (5) % $ (17,192) $ (27,463) 37 %
Adjusted EBITDA margin (1) (24) % (22) % (11) % (20) %
* Percentage calculated is not meaningful.
Note See accompanying footnotes on page 15.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands, unaudited)
Three Months Ended June 30, Six Months Ended June 30,
2024 2023 2024 2023
Operating activities
Net loss $ (27,968) $ (23,501) $ (44,952) $ (43,379)
Adjustments to reconcile net loss to net cash provided by operating activities
Depreciation and amortization 475 638 1,008 1,294
Amortization of internally developed software 3,803 4,513 7,676 9,102
Stock-based compensation expense 5,106 6,193 10,646 11,187
Deferred income taxes (1,249) (3,089) (2,631) (6,700)
Impairment charges 1,921 - 7,413 -
Other non-cash items (42) (162) (117) (101)
Changes in operating assets and liabilities
Accounts receivable 224 384 2,810 1,989
Contract assets - commissions receivable 13,602 12,505 86,697 95,012
Prepaid expenses and other assets 971 1 1,431 (124)
Accounts payable (1,537) 872 (2,474) (621)
Accrued compensation and benefits (20,920) (6,914) (20,788) 279
Accrued marketing expenses (1,562) (2,317) (12,498) (17,336)
Deferred revenue (6,046) 655 2,034 283
Accrued expenses and other liabilities 1,040 794 2,324 490
Net cash provided by (used in) operating activities (32,182) (9,428) 38,579 51,375
Investing activities
Capitalized internal-use software and website development costs (2,593) (2,038) (4,879) (4,202)
Purchases of property and equipment and other assets (261) (306) (465) (373)
Purchases of marketable securities (23,594) (26,593) (37,391) (48,602)
Proceeds from redemption and maturities of marketable securities 13,000 12,400 19,000 12,400
Net cash used in investing activities (13,448) (16,537) (23,735) (40,777)
Financing activities
Net proceeds from exercise of common stock options and employee stock purchases 354 262 354 262
Repurchase of shares to satisfy employee tax withholding obligations (596) (623) (1,851) (1,051)
Principal payments in connection with leases - (14) (4) (25)
Payments of preferred stock dividends (2,740) (873) (2,740) (873)
Net cash used in financing activities (2,982) (1,248) (4,241) (1,687)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (30) (235) 19 (127)
Net increase (decrease) in cash, cash equivalents and restricted cash (48,642) (27,448) 10,622 8,784
Cash, cash equivalents and restricted cash at beginning of period 178,076 183,872 118,812 147,640
Cash, cash equivalents and restricted cash at end of period $ 129,434 $ 156,424 $ 129,434 $ 156,424
(in thousands, unaudited)
We evaluate our business performance and manage our operations as two distinct reporting segments Medicare and Employer and Individual ("E I"). In the fourth quarter of 2023, the Individual, Family and Small Business segment was renamed "Employer and Individual". The E I segment name change was to the name only and had no impact on our historical financial position, results of operations, cash flow or segment level results previously reported. This identification of reportable segments is consistent with how the segments report to and are managed by our chief executive officer, who is our chief operating decision maker ("CODM"). The Medicare segment consists primarily of amounts earned from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans (collectively, the "Medicare Plans"), fees earned for the performance of administrative services, amounts earned from our non-broker of record arrangements, our performance of various post-enrollment services for members and to a lesser extent, amounts earned from our sale of ancillary products sold to our Medicare-eligible customers, including but not limited to, dental and vision plans, as well as amounts we are paid in connection with our advertising program for marketing and other services. The E I segment consists primarily of amounts earned from our sale of individual, family and small business health insurance plans, including both qualified and non-qualified plans, and ancillary products sold to our non-Medicare-eligible customers, including but not limited to, dental, vision, and short-term insurance. To a lesser extent, the E I segment consists of amounts earned from our online sponsorship and advertising program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website and our technology licensing and lead referral activities.
Marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect marketing and advertising, customer care and enrollment and technology and content operating expenses are allocated to each segment based on usage. Corporate consists of other general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization, which are managed in a corporate shared services environment and, since they are not the responsibility of segment operating management, are not allocated to the reportable segments and are instead reported within Corporate. Our results below reflect our updated methodology used in allocating certain expenses beginning in the first quarter of fiscal 2024, and results from the prior period presented have been recast to conform with the current period presentation. See accompanying footnotes on page 15 for further information.
The performance of each reportable segment is evaluated based on several factors, including revenue and segment profit (loss), which is calculated as total revenue for the applicable segment less direct and indirect allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization, impairment, restructuring and other charges, interest expense and other income (expense), net. Senior management uses segment profit (loss) to evaluate segment performance because they believe this measure is indicative of performance trends and the overall earnings potential of each segment.
Three Months Ended June 30, % Change Six Months Ended June 30, % Change
2024 2023 2024 2023
Revenue
Medicare $ 59,248 $ 55,430 7 % $ 141,636 $ 117,264 21 %
Employer and Individual 6,608 11,338 (42) % 17,184 23,227 (26) %
Total revenue $ 65,856 $ 66,768 (1) % $ 158,820 $ 140,491 13 %
Segment profit (loss) (8)
Medicare $ 1,274 $ (2,062) 162 % $ 9,583 $ (2,648) 462 %
Employer and Individual 890 6,888 (87) % 5,542 14,562 (62) %
Segment profit 2,164 4,826 (55) % 15,125 11,914 27 %
Corporate (8) (17,704) (19,634) (32,317) (39,377)
Stock-based compensation expense (5,106) (6,193) (10,646) (11,187)
Depreciation and amortization (4,278) (5,151) (8,684) (10,396)
Impairment, restructuring and other charges (3,035) - (9,348) -
Interest expense (2,849) (2,720) (5,658) (5,300)
Other income, net 2,335 2,828 4,726 4,816
Loss before income taxes $ (28,473) $ (26,044) (9) % $ (46,802) $ (49,530) 6 %
Note See accompanying footnotes on page 15.
(in thousands, unaudited)
Our commission revenue results from approval of an application from health insurance carriers, which we define as our customers under Accounting Standards Codification 606 - Revenue from Contracts with Customers ("ASC 606"). Our commission revenue is primarily comprised of commissions from health insurance carriers which is computed using the estimated constrained lifetime values of commission payments that we expect to receive. Our commissions may include certain bonus payments, which are generally based on our attaining predetermined target sales levels or other objectives, as determined by the health insurance carriers. For Medicare Advantage and Medicare Part D prescription drug plans, our commissions also include regular payments related to administrative services we perform.
The following table presents commission revenue by product for the periods indicated
Three Months Ended June 30, % Change Six Months Ended June 30, % Change
2024 2023 2024 2023
Medicare
Medicare Advantage $ 42,168 $ 45,389 (7) % $ 104,164 $ 99,510 5 %
Medicare Supplement 4,045 1,091 271 % 9,523 5,156 85 %
Medicare Part D 2,710 1,863 45 % 5,395 2,640 104 %
Total Medicare 48,923 48,343 1 % 119,082 107,306 11 %
Individual and Family
Non-Qualified Health Plans 388 2,989 (87) % 2,033 5,344 (62) %
Qualified Health Plans 710 1,752 (59) % 2,756 3,403 (19) %
Total Individual and Family 1,098 4,741 (77) % 4,789 8,747 (45) %
Ancillary 2,555 2,521 1 % 5,243 4,943 6 %
Small Business 2,563 3,800 (33) % 6,179 8,673 (29) %
Commission Bonus and Other 1,708 781 119 % 2,481 (1,480) 268 %
Total Commission Revenue $ 56,847 $ 60,186 (6) % $ 137,774 $ 128,189 7 %
The following table presents a summary of commission revenue by segment for the periods indicated
Three Months Ended June 30, Six Months Ended June 30,
2024 2023 2024 2023
Medicare
Commission revenue from members approved during the period $ 39,941 $ 36,006 $ 109,693 $ 92,623
Net commission revenue from members approved in prior periods (a) 10,681 13,403 11,683 13,455
Total Medicare segment commission revenue 50,622 49,409 121,376 106,078
Employer and Individual
Commission revenue from members approved during the period 3,265 3,298 8,942 10,006
Commission revenue from renewals of small business members during the period 2,142 2,158 5,170 5,271
Net commission revenue from members approved in prior periods (a) 818 5,321 2,286 6,834
Total Employer and Individual segment commission revenue 6,225 10,777 16,398 22,111
Total commission revenue $ 56,847 $ 60,186 $ 137,774 $ 128,189
(a) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net commission revenue from members approved in prior periods, or net adjustment revenue, includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. The total reductions to revenue from members approved in prior periods were $3.1 million and $2.9 million for the three months ended June 30, 2024 and 2023, respectively, and $3.6 million and $2.9 million for the six months ended June 30, 2024 and 2023, respectively. These reductions to revenue primarily relate to the Medicare segment.
SUMMARY OF SELECTED METRICS
(in thousands, except member and per member data, unaudited)
Selected Metrics - Second Quarter of 2024
Three Months Ended June 30, % Change
2024 2023
Approved Members (2)(a)
Medicare
Medicare Advantage 37,638 35,597 6 %
Medicare Supplement 1,954 2,923 (33) %
Medicare Part D 1,468 2,948 (50) %
Total Medicare 41,060 41,468 (1) %
Individual and Family 3,508 4,285 (18) %
Ancillary 11,078 13,051 (15) %
Small Business 922 1,964 (53) %
Total Approved Members 56,568 60,768 (7) %
(a) Medicare approved members were impacted by the shift in some broker of record arrangements to fee-based BPO arrangements in which we do not become the broker of record.
Constrained Lifetime Value of Commissions per Approved Member (3)
Medicare (b)
Medicare Advantage $ 927 $ 891 4 %
Medicare Supplement 1,112 875 27 %
Medicare Part D 225 231 (3) %
Individual and Family
Non-Qualified Health Plans 353 329 7 %
Qualified Health Plans 354 357 (1) %
Ancillary
Short-term 172 161 7 %
Dental 122 98 24 %
Vision 76 66 15 %
Small Business 253 229 10 %
(b) Constraint for Medicare Advantage was 5.5% and 7% for the three months ended June 30, 2024 and 2023, respectively. Constraints for all other Medicare products remained the same for the periods presented.
Expense Metrics per Approved Member (4)
Medicare
Customer care and enrollment cost per Medicare Advantage ("MA")-equivalent approved member (8) $ 599 $ 706 (15) %
Variable marketing cost per MA-equivalent approved member 457 396 15 %
Total acquisition cost per MA-equivalent approved member $ 1,056 $ 1,102 (4) %
Individual and Family Plan ("IFP")
Customer care and enrollment cost per IFP-equivalent approved member (8) $ 284 $ 230 23 %
Variable marketing cost per IFP-equivalent approved member 59 56 5 %
Total acquisition cost per IFP-equivalent approved member $ 343 $ 286 20 %
Note See accompanying footnotes on page 15.
SUMMARY OF SELECTED METRICS
(in thousands, except member and per member data, unaudited)
Selected Metrics - Six Months Ended June 30, 2024
Six Months Ended June 30, % Change
2024 2023
Approved Members (2)(a)
Medicare
Medicare Advantage 103,388 96,048 8 %
Medicare Supplement 8,136 7,508 8 %
Medicare Part D 5,043 6,794 (26) %
Total Medicare 116,567 110,350 6 %
Individual and Family 10,668 14,384 (26) %
Ancillary 25,028 29,707 (16) %
Small Business 2,564 3,903 (34) %
Total Approved Members 154,827 158,344 (2) %
(a) Medicare approved members were impacted by the shift in some broker of record arrangements to fee-based BPO arrangements in which we do not become the broker of record.
As of June 30, % Change
2024 2023
Estimated Membership (5) (b)
Medicare (6)
Medicare Advantage 584,649 572,799 2 %
Medicare Supplement 97,426 94,372 3 %
Medicare Part D 195,671 211,144 (7) %
Total Medicare 877,746 878,315 - %
Individual and Family (6) 79,786 90,082 (11) %
Ancillary (6) 174,107 196,141 (11) %
Small Business (7) 45,101 46,560 (3) %
Total Estimated Membership 1,176,740 1,211,098 (3) %
(b) Medicare estimated membership was impacted by the shift in some broker of record arrangements to fee-based BPO arrangements in which we do not become the broker of record.
Note See accompanying footnotes on page 15.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Reconciliation of GAAP Operating Costs and Expenses to Non-GAAP Operating Costs and Expenses(1) (in thousands)
Three Months Ended June 30, Six Months Ended June 30,
2024 2023 2024 2023
GAAP marketing and advertising expense (8) $ 26,783 $ 23,439 $ 65,520 $ 56,308
Stock-based compensation expense (711) (538) (1,355) (993)
Non-GAAP marketing and advertising expense (1) $ 26,072 $ 22,901 $ 64,165 $ 55,315
GAAP customer care and enrollment expense (8) $ 28,551 $ 29,979 $ 61,452 $ 55,050
Stock-based compensation expense (511) (788) (1,035) (1,393)
Non-GAAP customer care and enrollment expense (1) $ 28,040 $ 29,191 $ 60,417 $ 53,657
GAAP technology and content expense (8) $ 13,044 $ 14,453 $ 26,349 $ 28,806
Stock-based compensation expense (779) (1,173) (1,753) (2,078)
Non-GAAP technology and content expense (1) $ 12,265 $ 13,280 $ 24,596 $ 26,728
GAAP general and administrative expense (8) $ 22,402 $ 25,049 $ 42,021 $ 49,373
Stock-based compensation expense (3,105) (3,694) (6,503) (6,723)
Non-GAAP general and administrative expense (1) $ 19,297 $ 21,355 $ 35,518 $ 42,650
GAAP operating costs and expenses $ 93,815 $ 92,920 $ 204,690 $ 189,537
Stock-based compensation expense (5,106) (6,193) (10,646) (11,187)
Impairment, restructuring and other charges (3,035) - (9,348) -
Non-GAAP operating costs and expenses (1) $ 85,674 $ 86,727 $ 184,696 $ 178,350
Reconciliation of GAAP Total Revenue to Non-GAAP Total Revenue Excluding Net Adjustment Revenue(1) (in thousands)
Three Months Ended June 30, $ Change % Change
2024 2023
GAAP total revenue $ 65,856 $ 66,768 $ (912) (1)%
Net adjustment revenue (11,499) (18,724)
Non-GAAP total revenue excluding net adjustment revenue (1) $ 54,357 $ 48,044 $ 6,313 13%
Note See accompanying footnotes on page 15.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Reconciliation of GAAP Net Loss to Non-GAAP Net Loss(1) and GAAP Net Loss to Adjusted EBITDA Excluding Net Adjustment Revenue(1) (in thousands)
Three Months Ended June 30, $ Change % Change
2024 2023
GAAP net loss $ (27,968) $ (23,501) $ (4,467) (19)%
Net adjustment revenue (11,499) (18,724)
Impairment, restructuring and other charges 3,035 -
Adjustment to benefit from income taxes, net 2,115 4,500
Non-GAAP net loss (1) (34,317) (37,725) 3,408 9%
Stock-based compensation expense 5,106 6,193
Depreciation and amortization 4,278 5,151
Interest expense 2,849 2,720
Other income, net (2,335) (2,828)
Adjustment to benefit from income taxes, net (2,115) (4,500)
Benefit from income taxes (505) (2,543)
Adjusted EBITDA excluding net adjustment revenue (1) $ (27,039) $ (33,532) $ 6,493 19%
Reconciliation of GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA(1) (in thousands) and Adjusted EBITDA Margin(1)
Three Months Ended June 30, Six Months Ended June 30,
2024 2023 2024 2023
GAAP net loss attributable to common stockholders $ (38,988) $ (32,915) $ (66,699) $ (60,963)
Preferred stock dividends 5,480 5,223 10,960 10,324
Change in preferred stock redemption value 5,540 4,191 10,787 7,260
GAAP net loss (27,968) (23,501) (44,952) (43,379)
Stock-based compensation expense 5,106 6,193 10,646 11,187
Depreciation and amortization 4,278 5,151 8,684 10,396
Impairment, restructuring and other charges 3,035 - 9,348 -
Interest expense 2,849 2,720 5,658 5,300
Other income, net (2,335) (2,828) (4,726) (4,816)
Benefit from income taxes (505) (2,543) (1,850) (6,151)
Adjusted EBITDA (1) $ (15,540) $ (14,808) $ (17,192) $ (27,463)
Net loss margin (42) % (35) % (28) % (31) %
Adjusted EBITDA margin (1) (24) % (22) % (11) % (20) %
Note See accompanying footnotes on page 15.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Reconciliation of Medicare Segment Revenue to Non-GAAP Medicare Segment Revenue(1) (in thousands)
Three Months Ended June 30, $ Change % Change
2024 2023
Medicare segment revenue $ 59,248 $ 55,430 $ 3,818 7 %
Medicare net adjustment revenue (10,681) (13,403) 2,722 20 %
Non-GAAP Medicare segment revenue (1) $ 48,567 $ 42,027 $ 6,540 16 %
Reconciliation of E I Segment Revenue to Non-GAAP E I Segment Revenue(1) (in thousands)
Three Months Ended June 30, $ Change % Change
2024 2023
E I segment revenue $ 6,608 $ 11,338 $ (4,730) (42) %
E I net adjustment revenue (818) (5,321) 4,503 85 %
Non-GAAP E I segment revenue (1) $ 5,790 $ 6,017 $ (227) (4) %
Reconciliation of Segment Profit (Loss) to Segment Profit (Loss) Excluding Net Adjustment Revenue(1), Medicare Segment Profit (Loss) to Medicare Segment Profit (Loss) Excluding Net Adjustment Revenue(1) and E I Segment Profit (Loss) to E I Segment Profit (Loss) Excluding Net Adjustment Revenue(1) (in thousands)
Three Months Ended June 30, $ Change % Change
2024 2023
Segment profit (8) $ 2,164 $ 4,826 $ (2,662) (55) %
Net adjustment revenue (11,499) (18,724) 7,225 39 %
Segment loss excluding net adjustment revenue (1) $ (9,335) $ (13,898) 4,563 33 %
Medicare segment profit (loss) (8) $ 1,274 $ (2,062) $ 3,336 162 %
Medicare net adjustment revenue (10,681) (13,403) 2,722 20 %
Medicare segment loss excluding net adjustment revenue (1) $ (9,407) $ (15,465) $ 6,058 39 %
E I segment profit (8) $ 890 $ 6,888 $ (5,998) (87) %
E I net adjustment revenue (818) (5,321) 4,503 85 %
E I segment profit excluding net adjustment revenue (1) $ 72 $ 1,567 $ (1,495) (95) %
Note See accompanying footnotes on page 15.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
Reconciliation of Guidance GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA(1) (in millions)
Full Year 2024 Guidance
Low High
GAAP net loss attributable to common stockholders $ (81.5) $ (67.0)
Impact from preferred stock 45.0 45.0
GAAP net loss (36.5) (22.0)
Stock-based compensation expense 20.0 17.0
Depreciation and amortization 19.0 18.0
Impairment, restructuring and other charges 9.0 9.0
Interest expense 11.0 10.0
Other income, net (8.0) (9.0)
Provision for (benefit from) income taxes (7.0) 2.0
Adjusted EBITDA (1) $ 7.5 $ 25.0
Reconciliation of Guidance GAAP Total Revenue to Guidance Non-GAAP Total Revenue Excluding Net Adjustment Revenue(1) (in millions)
Full Year 2024 Guidance Mid Guidance YoY
Low Mid High FY 2023 % Change
GAAP total revenue $ 470.0 $ 482.5 $ 495.0 $ 453.0 7 %
Net adjustment revenue (14.0) (17.0) (20.0) (48.0) 65 %
Non-GAAP total revenue excluding net adjustment revenue (1) $ 456.0 $ 465.5 $ 475.0 $ 405.0 15 %
Note See accompanying footnotes on page 15.
Footnotes to Preceding Financial Statements and Metrics

Frequently Asked Questions

What drove eHealth's Q2 2024 financial results?

Strong growth in the Medicare segment year-over-year.

How did eHealth's Q2 2024 total revenue compare to last year?

Total revenue was $65.9 million, a 1% decrease from Q2 2023.

What is eHealth's outlook for 2024 revenue?

eHealth expects total revenue between $470 million and $495 million.

What improvement did eHealth see in adjusted EBITDA?

Adjusted EBITDA improved to $(15.5) million from $(14.8) million.

How much cash and equivalents did eHealth have as of June 30, 2024?

eHealth had $151.1 million in cash, cash equivalents, and marketable securities.

Last updated: Aug 7, 2024